R&D Parkinson’s Awareness Month may end, but the research impera... As Parkinson’s Awareness Month comes to a close, the urgency to challenge the status quo has never been greater.
R&D Parkinson’s disease: Transitioning from symptom control to d... The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
News Parkinson's charity partners Biognosys on biomarker project A new R&D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.
News AC Immune says Parkinson's drug slows progression AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.
News Merck partners Valo on $3bn, AI-based Parkinson's project Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.
News UK starts 'largest-ever' trial of possible Parkinson's drugs UK researchers have started a large-scale trial to test a battery of potential Parkinson's drugs to see if they can slow down disease progression.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
